Selected trials that investigated novel additions added to CHOP backbone for frontline treatment of PTCL
| Treatment regimen . | Phase . | # evaluable patients . | ORR . | PFS . | OS . | Toxicities . | Reference . |
|---|---|---|---|---|---|---|---|
| Romidepsin + CHOP | 3 | 211 | 63% | Median 12 mo | Median 51.8 mo | G ≥ 3 thrombocytopenia 50%, neutropenia 49%, anemia 47% | 5 |
| BV-CHP | 3 | 226 | 83% | 5 yr 51% | 5 yr 70.1% | G ≥ 3 neuropathy 4% | 7 |
| Pralatrexate-CEOP | 2 | 33 | 70% | 2 yr 39% | 2 yr 60% | G ≥ 3 mucositis 18% | 34 |
| CHOEP Lenalidomide | 1 | 39 | 69% | 2 yr 55% | 2 yr 78% | G ≥ 3 febrile neutropenia 35% | 35 |
| CHOP + vorinostat | 1 | 12 | 93% | 2 yr 79% | 2 yr 81% | MTD 300 mg daily, diarrhea 63% | 36 |
| CHOP + oral azacitidine (CC-486) | 2 | 20 | (75% CR) | 2 yr 65.8% | 2 yr 68.4% | G ≥ 3 neutropenia 71% | 9 |
| CHOP + pralatrexate | 1 | 50 | 86% | NR | NR | 67% G ≥ 3 TEAEs, most commonly anemia (21%) | 6 |
| Treatment regimen . | Phase . | # evaluable patients . | ORR . | PFS . | OS . | Toxicities . | Reference . |
|---|---|---|---|---|---|---|---|
| Romidepsin + CHOP | 3 | 211 | 63% | Median 12 mo | Median 51.8 mo | G ≥ 3 thrombocytopenia 50%, neutropenia 49%, anemia 47% | 5 |
| BV-CHP | 3 | 226 | 83% | 5 yr 51% | 5 yr 70.1% | G ≥ 3 neuropathy 4% | 7 |
| Pralatrexate-CEOP | 2 | 33 | 70% | 2 yr 39% | 2 yr 60% | G ≥ 3 mucositis 18% | 34 |
| CHOEP Lenalidomide | 1 | 39 | 69% | 2 yr 55% | 2 yr 78% | G ≥ 3 febrile neutropenia 35% | 35 |
| CHOP + vorinostat | 1 | 12 | 93% | 2 yr 79% | 2 yr 81% | MTD 300 mg daily, diarrhea 63% | 36 |
| CHOP + oral azacitidine (CC-486) | 2 | 20 | (75% CR) | 2 yr 65.8% | 2 yr 68.4% | G ≥ 3 neutropenia 71% | 9 |
| CHOP + pralatrexate | 1 | 50 | 86% | NR | NR | 67% G ≥ 3 TEAEs, most commonly anemia (21%) | 6 |
Mo, months; MTD, maximum tolerated dose; NR, not reported; yr, year.